Lisaftoclax
A Bcl-2 inhibitor used in cancer treatment
| Lisaftoclax | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Lisaftoclax is a small molecule Bcl-2 inhibitor that is being investigated for its potential use in the treatment of various types of cancer. It is designed to induce apoptosis in cancer cells by inhibiting the Bcl-2 protein, which is often overexpressed in cancerous cells and contributes to their survival.
Mechanism of Action[edit | edit source]
Lisaftoclax functions by targeting the Bcl-2 protein, a member of the Bcl-2 family of proteins that regulate cell death (apoptosis). Bcl-2 is an anti-apoptotic protein that helps cancer cells evade the normal process of programmed cell death, allowing them to survive and proliferate. By inhibiting Bcl-2, lisaftoclax promotes apoptosis in cancer cells, thereby reducing tumor growth.
Development and Clinical Trials[edit | edit source]
Lisaftoclax is currently undergoing clinical trials to evaluate its safety and efficacy in humans. These trials are crucial for determining the appropriate dosing, potential side effects, and therapeutic benefits of the drug. The development of lisaftoclax is part of a broader effort to create targeted therapies that specifically attack cancer cells while minimizing damage to normal cells.
Potential Applications[edit | edit source]
Lisaftoclax is being studied for its potential use in treating several types of cancer, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and other hematological malignancies. Its ability to specifically target the Bcl-2 protein makes it a promising candidate for combination therapies, where it can be used alongside other treatments to enhance overall efficacy.
Challenges and Considerations[edit | edit source]
While lisaftoclax shows promise, there are challenges associated with its development and use. These include managing potential side effects, such as tumor lysis syndrome, which can occur when a large number of cancer cells die rapidly. Additionally, researchers are investigating the potential for resistance to lisaftoclax, which could limit its long-term effectiveness.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
